Nkarta Therapeutics
- Founded: 2015
- Location: South SF, CA
- Employee range: 50 - 200
- Clinical stage: Clin1
- Therapy area: AML , MDS
- Drug types: ONC
- Lead product: NKX101
- Product link: https://www.nkartatx.com/pipeline/
- Funding: $200M stock Apr 2022; $289.8M IPO Jul 2020; $114M B Sep 2019; $11M 2015
- Investors: Samsara, NEA Ventures, SR One, Novo Holdings, Amgen Ventures, Deerfield Management, Life Science Partners, Logos Capital and RA Capital Management
nkartatx.com linkedin.com job board
Short description:
Allogeneic cellular immunotherapy platform
Drug notes:
Also Clin0 multiple cancers; NKX019 Clin1 B cell malignancies; undisclosed RD oncology; undisclosed RD undisclosed
Long description:
Contact us to add description.
Jobs:
© 2023 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com